Navigation Links
AMT Intends to Incorporate Additional Data to its Marketing Authorization Dossier for Glybera(R)
Date:10/3/2008

AMSTERDAM, October 3 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it intends to incorporate additional data into the Marketing Authorization Application (MAA) for Glybera(R) for Lipoprotein Lipase Deficiency (LPLD), a seriously debilitating and potentially lethal disease.

The data obtained so far from two phase II clinical studies (22 patients in total) demonstrate that Glybera(R) is well-tolerated (no drug-related severe adverse events and no dose-limiting toxicity). Positive effects were shown on fat (triglyceride) metabolism, resulting in an almost complete disappearance of pancreatitis during both the immediate 12-week study observation period and the long-term follow-up (up to 3 years post-injection), as well as the disappearance or reduction of fat accumulations in skin or retina. All patients reported gain of energy and in the two patients that had diabetes, a reduction of insulin resistance was observed, leading to a reduction of their diabetic medication.

In consultation with the Rapporteur countries, Germany and the United Kingdom, of the European Medicines Agency (EMEA) and Health Canada, AMT has decided to expand the clinical experience and to augment the Marketing Authorization Application (MAA) with an additional 16-patient study that will investigate the broader impact of this gene therapy on additional aspects of lipid metabolism. Preparations for this study to be conducted in Canada will start immediately. Submission of the MAA to the EMEA is foreseen in the second half of 2009. In line with the guidance given in the half year financial report, the Company's cash position allows the completion of this study to be done with existing financial resources.

AMT has developed Glybera(R) as a cure for patients with the rare genetic disorder, LPLD. Because of a defective gene, LPLD patients do not produce an enzyme that normally break
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Incorporated Announces Third Quarter 2007 Financial Results
3. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
4. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
7. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
8. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
9. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
10. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
11. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... SKIPPACK, Pa., Dec. 14 At GeoInvesting.com, we ... ) for some time now. Our largest hang up ... Although the Company,s fiscal June 2010 net income guidance ... fiscal 2009 reported net income of $7.9 million, the ... term EPS growth scenario, which depends upon the share ...
(Date:12/14/2009)... BERKELEY HEIGHTS, N.J., Dec. 14 ... a worldwide provider of secure Health Information ... that Home Care of the Carolinas ("HCC"), ... Inc. ("AMI"), a durable medical equipment supplier, ... to streamline and standardize processes for the ...
(Date:12/14/2009)... WALTHAM, Mass., Dec. 14 According ... authority on medical technology market intelligence, Japan,s ... process has created a significant lag in ... country compared to other developed nations. ... Vascular Devices 2010 report finds, however, ...
Breaking Medicine Technology:GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms 2Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidate's Inscrybe Healthcare to Improve Care Order Processing 2Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidate's Inscrybe Healthcare to Improve Care Order Processing 3Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidate's Inscrybe Healthcare to Improve Care Order Processing 4Japanese Peripheral Vascular Stent Procedures to Experience 11% Growth Through 2014 2Japanese Peripheral Vascular Stent Procedures to Experience 11% Growth Through 2014 3Collagen deficient mice show signs of osteoarthritis 55468 1Collagen deficient mice show signs of osteoarthritis 55468 2Senator Ted Kennedy 3A A Member of the NAMI Family 55466 1Senator Ted Kennedy 3A A Member of the NAMI Family 55466 2NAPHS Statement on Death of Sen Edward M Kennedy 55461 1
... 4 Pharmacopeia (Nasdaq:,PCOP), an innovator in the ... announced that Dr. Leslie J. Browne, President,and Chief ... the,BIO CEO & Investor Conference 2008. The conference ... Hotel in New York City., Dr. Browne,s ...
... 4 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) ... Health and Human Services (DHHS) recommend that a,co-receptor ... be,performed whenever the use of a CCR5 inhibitor ... patients who exhibit virologic failure on a,CCR5 inhibitor., ...
Other Medicine Technology:Pharmacopeia to Present at BIO CEO & Investor Conference 2008 2Pharmacopeia to Present at BIO CEO & Investor Conference 2008 3DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use 2DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use 3DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use 4DHHS Guidelines Support Use of Trofile(TM) Assay Prior to CCR5 Inhibitor Use 5
(Date:12/14/2009)... 14 United Dental Care (also known as ... providers of top-notch dental care in Southern California. We ... kid,s dentistry, braces (orthodontics) and periodontal treatments. Beverly ... offices are staffed with experienced and trusted dentists ... Dr. Eftekhari (Dr. E) is one of these trusted ...
(Date:12/14/2009)... ... La Jolla, Calif. (Vocus) -- The physicians at Scripps ... new chief of staff of the 372-bed facility. Dr. Sedwitz will ... 1, 2010. , , , , ,During his two-year term, Dr. ... administrative staff and its board of directors. Dr. Sedwitz will play ...
(Date:12/14/2009)... & Ellis Healthcare REIT II, Inc. announced today that its ... of record as of the close of business on each ... ending on Feb. 28, 2010. The distributions will be ... will be equal to an annualized distribution rate of 6.5 ... These distributions will be aggregated and paid in cash monthly ...
(Date:12/14/2009)... linked to scans performed in 2007 , , MONDAY, Dec. ... patients to far more radiation than previously thought and in ... year, two new studies claim. , Based on the findings, ... of Internal Medicine , the study authors, joined by ... clinicians to limit radiation exposure to patients. , "CT has ...
(Date:12/14/2009)... underdiagnosed, poorly treated and highly stigmatized, according to ... Rubin, M.D., Ph.D. So these Washington University physicians ... , In "Demystifying Psychiatry," Zorumski and Rubin, who ... psychiatric patients and helping patient families, say some ... treatment result from a lack of understanding psychiatry ...
Breaking Medicine News(10 mins):Health News:United Dental Care, Gentle Care, Trusted Dentists 2Health News:United Dental Care, Gentle Care, Trusted Dentists 3Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:Book demystifies psychiatry for the general public 2Health News:Book demystifies psychiatry for the general public 3
... major Wyeth Tuesday launched its blockbuster vaccine Prevenar ... among infants and toddlers//. ,Pneumococcal disease is ... also known as the "pneumococcus" bacteria. ... expected to prevent pneumococcal diseases like sepsis, meningitis, ...
... the scarcity of doctors in rural areas, the Goa government ... medical colleges// to serve in such regions for five years, ... cabinet decided that authorities would invoke the bond to be ... for five years, he told reporters after the cabinet meeting., ...
... ,Recent research has further confirmed the theory that environmental ... for diabetes //in children and young adults. ... Universities and Leeds Teaching Hospitals NHS Trust, carried out ... on the times and places where the children and ...
... conducted by the researchers at the Imperial College London it ... than the others//. , It was believed ... It was found that lab workers who frequently handled research ... exposure to dogs appeared to be protective against eczema allergy. ...
... American has a stroke, caused either by a blocked or burst ... them will die. ,That's the bad news. ,And the ... fix the problems that cause many strokes — before a stroke ... open up the skull. ,New technologies, delivered to the ...
... has been slightly unconscious and has recovered after a period of ... a car crash and he was in a state of partial ... nods. But now his speech and movement were slowly improving. The ... brain slowly started to rewire. ,He is the ...
Other Medicine News:Health News:Environmental Factors Trigger Onset of Diabetes 2Health News:Brain Surgery Without the Surgery? 2Health News:Brain Surgery Without the Surgery? 3Health News:Brain Surgery Without the Surgery? 4Health News:Brain Surgery Without the Surgery? 5Health News:Brain Surgery Without the Surgery? 6
For the quantitative determination of iron, total iron-binding capacity in human serum....
HDL Cholesterol, liquid....
Cholesterol/HDL with 200 tests....
For the quantitative determination of High Density Lipoprotein in serum. Available in liquid type. Polyethylene glycol (6000) precipitating reagent. Linearity: 200 mg/dl....
Medicine Products: